208 related articles for article (PubMed ID: 36321555)
1. Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis.
Jin P; Jiang J; Zhou L; Huang Z; Qin S; Chen HN; Peng L; Zhang Z; Li B; Luo M; Zhang T; Ming H; Ding N; Li L; Xie N; Gao W; Zhang W; Nice EC; Wei Y; Huang C
EMBO Mol Med; 2022 Dec; 14(12):e16082. PubMed ID: 36321555
[TBL] [Abstract][Full Text] [Related]
2. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
3. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue.
Whitaker-Menezes D; Martinez-Outschoorn UE; Flomenberg N; Birbe RC; Witkiewicz AK; Howell A; Pavlides S; Tsirigos A; Ertel A; Pestell RG; Broda P; Minetti C; Lisanti MP; Sotgia F
Cell Cycle; 2011 Dec; 10(23):4047-64. PubMed ID: 22134189
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair.
Liu J; Hou M; Yuan T; Yi G; Zhang S; Shao X; Chen J; Jia X; He Z
Oncol Rep; 2012 Oct; 28(4):1406-12. PubMed ID: 22843031
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer.
Feng J; Lu H; Ma W; Tian W; Lu Z; Yang H; Cai Y; Cai P; Sun Y; Zhou Z; Feng J; Deng J; Shu Y; Qu K; Jia W; Gao P; Zhang H
Protein Cell; 2022 Nov; 13(11):825-841. PubMed ID: 35217990
[TBL] [Abstract][Full Text] [Related]
6. Why Metformin Should Not Be Used as an Oxidative Phosphorylation Inhibitor in Cancer Patients.
Sakellakis M
Chemotherapy; 2023; 68(4):185-189. PubMed ID: 37343530
[TBL] [Abstract][Full Text] [Related]
7. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells.
Saito T; Chiba T; Yuki K; Zen Y; Oshima M; Koide S; Motoyama T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Tada M; Kanai F; Takiguchi Y; Iwama A; Yokosuka O
PLoS One; 2013; 8(7):e70010. PubMed ID: 23922888
[TBL] [Abstract][Full Text] [Related]
8. Expression of TOMM34 and Its Clinicopathological Correlations in Urothelial Carcinoma of the Bladder.
Ahmed MAH; Ali MH; Abbas HH; Elatrash GA; Foda AAM
Pathol Oncol Res; 2020 Jan; 26(1):411-418. PubMed ID: 30382527
[TBL] [Abstract][Full Text] [Related]
9. High Expression of Tomm34 and Its Correlations With Clinicopathology in Oral Squamous Cell Carcinoma.
Cai M; Tan R; Huang Y; Chen X; Kong Q; Guo K; Xu M
Pathol Oncol Res; 2021; 27():641042. PubMed ID: 34257607
[TBL] [Abstract][Full Text] [Related]
10. Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells.
Harati R; Vandamme M; Blanchet B; Bardin C; Praz F; Hamoudi RA; Desbois-Mouthon C
Mol Pharmacol; 2021 Jul; 100(1):32-45. PubMed ID: 33990407
[TBL] [Abstract][Full Text] [Related]
11. Metformin Enhances the Effect of Regorafenib and Inhibits Recurrence and Metastasis of Hepatic Carcinoma After Liver Resection via Regulating Expression of Hypoxia Inducible Factors 2α (HIF-2α) and 30 kDa HIV Tat-Interacting Protein (TIP30).
Yang Q; Guo X; Yang L
Med Sci Monit; 2018 Apr; 24():2225-2234. PubMed ID: 29654226
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
[TBL] [Abstract][Full Text] [Related]
13. Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: targeting AMPK activation to control migration.
Ferretti AC; Hidalgo F; Tonucci FM; Almada E; Pariani A; Larocca MC; Favre C
Sci Rep; 2019 Feb; 9(1):2815. PubMed ID: 30809021
[TBL] [Abstract][Full Text] [Related]
14. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
[TBL] [Abstract][Full Text] [Related]
15. Caffeic Acid and Metformin Inhibit Invasive Phenotype Induced by TGF-β1 in C-4I and HTB-35/SiHa Human Cervical Squamous Carcinoma Cells by Acting on Different Molecular Targets.
Tyszka-Czochara M; Lasota M; Majka M
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29337896
[TBL] [Abstract][Full Text] [Related]
16. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
Cai X; Hu X; Cai B; Wang Q; Li Y; Tan X; Hu H; Chen X; Huang J; Cheng J; Jing X
Oncol Rep; 2013 Nov; 30(5):2449-57. PubMed ID: 24008375
[TBL] [Abstract][Full Text] [Related]
17. Glibenclamide Mimics Metabolic Effects of Metformin in H9c2 Cells.
Salani B; Ravera S; Fabbi P; Garibaldi S; Passalacqua M; Brunelli C; Maggi D; Cordera R; Ameri P
Cell Physiol Biochem; 2017; 43(3):879-890. PubMed ID: 28954268
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application.
Abdelhamid AM; Saber S; Youssef ME; Gaafar AGA; Eissa H; Abd-Eldayem MA; Alqarni M; Batiha GE; Obaidullah AJ; Shahien MA; El-Ahwany E; Amin NA; Etman MA; Kaddah MMY; Abd El-Fattah EE
Biomed Pharmacother; 2022 Jan; 145():112455. PubMed ID: 34844106
[TBL] [Abstract][Full Text] [Related]
19. Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread.
Giannoni E; Taddei ML; Morandi A; Comito G; Calvani M; Bianchini F; Richichi B; Raugei G; Wong N; Tang D; Chiarugi P
Oncotarget; 2015 Sep; 6(27):24061-74. PubMed ID: 26183399
[TBL] [Abstract][Full Text] [Related]
20. Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP.
Tian Y; Tang B; Wang C; Sun D; Zhang R; Luo N; Han Z; Liang R; Gao Z; Wang L
Oncotarget; 2016 Jul; 7(29):46230-46241. PubMed ID: 27323827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
